Refers to disease or attack onInflammation of the optic nerve that may be classified as unilateral (affecting one eye) or bilateral (affecting both eyes) that may result in vision changes, vision loss, and/or pain with eye movement. two sides.
Related Posts
The MOG Project Applauds Results from the Hoffmann-La Roche & Genentech Clinical Trial
Results point to Enspryng® (satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammationA process of the immune system that involves chemicals released by immune cells (i.e. white blood cells) inducing localized heat, swelling, redness, and pain to an area that occurs when tissue becomes damaged or infected from a pathogen, and usually results in the desctruction and removal of the pathogen and/or healing to the tissue. In the case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD), inflammation is the result of the incorrect targeting of the myelin oligodendrocyte glycoprotein (MOG) by the immune system, resulting in damage to myelin sheaths. Washington, DC – (April 21, 2026) The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project is thrilled
Read More »The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project Applauds Results from the Hoffmann-La Roche & Genentech Clinical TrialResearch studies performed using people as subjects that are aimed at evaluating a medical, surgical, or behavioral intervention to determine to what degree a new treatment (e.g., drugs or medical devices) is safe and effective for general populations.
The MOG Project Awards 2025 Research Grants
The MOG Project’s Research for Rare program has awarded our 2025 MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease global research grants: the Apollo Grant and the Accelerator Grant. These grants are